|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| KPRssrGsIFtFRRR SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 451569 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Putative in vivo kinases: | |
| Kinases, in vitro: | |
| Treatments: | |
| Downstream Regulation | |
|---|---|
| Effects of modification on SCN5A: | |
| Disease / Diagnostics Relevance | |
|---|---|
| Relevant diseases: | |
| References | |
|---|---|
|
Herren AW, et al. (2015) CaMKII Phosphorylation of Na(V)1.5: Novel in Vitro Sites Identified by Mass Spectrometry and Reduced S516 Phosphorylation in Human Heart Failure. J Proteome Res 14, 2298-311
25815641 Curated Info |
|
|
Aiba T, et al. (2014) A mutation causing brugada syndrome identifies a mechanism for altered autonomic and oxidant regulation of cardiac sodium currents. Circ Cardiovasc Genet 7, 249-56
24795344 Curated Info |
|
|
Possemato A (2007) CST Curation Set: 2928; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
|
Zhou J, et al. (2002) Phosphorylation and putative ER retention signals are required for protein kinase A-mediated potentiation of cardiac sodium current. Circ Res 91, 540-6
12242273 Curated Info |
